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Abstract
Background and Methods: This study evaluates the antihypertensive effect of long-term intake of a soluble
cocoa fiber product (SCFP). Different doses of SCFP were evaluated (200, 400, and 800 mg/kg/day) and a
dose of 800 mg/kg/day of beta-glucan 0.75 (BETA-G) was used as a standard fiber. Water, a neutral vehicle,
was used as negative control, and 50 mg/kg/day captopril was used as positive control. Systolic blood pressure
(SBP) was measured weekly by the tail cuff method. Body weight, food, and liquid intake were also registered
weekly in the rats from 10 to 24 weeks of life. Glucose, total cholesterol, and triglyceride levels; redox status;
and the angiotensin-converting enzyme activity were also studied in the plasma samples of these animals.
Results: Throughout the 10 weeks of treatment, captopril and SCFP (400 mg/kg/day) demonstrated blood
pressure lowering effects in the spontaneously hypertensive rats (pB0.05; n8). Paradoxically, neither the
highest dose (800 mg/kg/day) of SCFP decreased SBP nor 800 mg/kg/day BETA-G (p0.05; n8). When
the corresponding antihypertensive treatment, was disrupted the SBP values of the 400 mg/kg/day SCFP
treated animals returned to control values (p0.05; n8). In addition, the SCFP significantly decreased
(pB0.05; n4) the glucose, cholesterol, and triglyceride levels and also the liver and plasma malondaldehyde
levels. Moreover, the SCFP slightly increased the reduced glutathione levels in the liver.
Conclusion: The SCFP could be used to control the blood pressure of hypertensive subjects for a long period
of time and could improve metabolic complications associated to cardiovascular diseases.
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S
ome food compounds may exert biological activ-
ities, and nowadays there is a growing interest
on functional foods that could control arterial
blood pressure. Functional foods are foods that show
healthy properties besides their nutritional value. In
particular, the close relationship between the consump-
tion of foods rich in antioxidants and the drop of arterial
blood pressure has assumed great importance in recent
times, emerging as a non-pharmacological antihyperten-
sive strategy (1, 2).
Dietary fiber includes a group of food components,
present in cereals, fruits, and vegetables, which are re-
sistant to digestive enzymes. Attending to its water solu-
bility, fiber can be classified into insoluble and soluble
fiber (3). Dietary fiber has demonstrated beneficial effects
on different cardiovascular risk factors such as obesity
(4, 5), hyperglycaemia and diabetes mellitus type 2 (6, 7),
and hypercholesterolemia (8, 9). Even though essential
hypertension is a well-known risk factor for cardiovas-
cular disorders, the effect of dietary fiber on arterial blood
pressure has been studied less than its effect on the above-
mentioned cardiovascular risk factors.
Recent research has been focused on cocoa and its
products because of their antihypertensive properties
that can be attributed to their high antioxidant poly-
phenol content (10, 11). Data show that sustained chronic
consumption of cocoa products can lead to a relatively
low accumulation of cocoa polyphenols in human plasma,
sufficient to exert some health-relevant bioactivity (12).
The aim of the study is to evaluate the antihypertensive
properties of a soluble cocoa fiber product (SCFP) that
was obtained by a patented enzymatic process from cocoa
husk, in spontaneously hypertensive rats (SHR) (13). The
SCFP had previously demonstrated beneficial effects on
the body weight and the lipid profile of hypercholester-
olemic Sprague-Dawley rats (14) and produced positive
effects on hyperglycaemia, hypercholesterolemia and
arterial blood pressure in Zu¨cker fatty rats (15). There-
fore, in this study, we have also investigated the effect of
the long-term intake of SCFP on the body weight,
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glycaemia, cholesterol, and triglyceride plasma levels of
the treated SHR. Furthermore, the redox status and the
plasma angiotensin-converting enzyme (ACE) activity
were also determined in these animals.
Materials and methods
Soluble cocoa fiber product
The chemical composition, polyphenol content, and anti-
oxidant capacity of SCFP were characterized by Ramos
et al. (14). Table 1 shows the more relevant information
reported by these researchers for the present study.
Protocol in rats
Forty-eight 10-week-old male SHR, weighing 255265 g,
were purchased from Charles River Laboratories (Barce-
lona-Spain) for this study. These animals were caged
in groups of four rats, at a temperature of 238C, with 12 h
light/dark cycles. They were in turn randomly divided
into six groups of eight animals with ad libitum intake.
Throughout the experimental period, the SHR of the
established groups were fed a standard diet (A04 Panlab,
Barcelona-Spain). From the 10th week of life until
the animals were 20 weeks old (treatment period), the
consumption of drinking fluids in these groups was as
follows: tap water (neutral vehicle as negative control
group), 200 mg/kg/day SCFP, 400 mg/kg/day SCFP,
800 mg/kg/day SCFP, 800 mg/kg/day beta-glucan 0.75
(BETA-G) (fiber reference group), and 50 mg/kg/day
captopril (positive control group). From 20 to 24 weeks
of life (follow-up period), all groups consumed tap water
as a drinking fluid. Weekly body weight of all animals
was recorded up to the 24th week of life. Daily intake
of drinking fluids and freely accessible feed was also
estimated weekly in the animals from the different groups
throughout the experimental period. Four 20-week-old
rats of each group were killed by decapitation. Blood and
liver samples were quickly collected from these animals for
future analytical evaluations. Glucose, total cholesterol,
triglyceride, and malondialdehyde (MDA) levels were
determined in the plasma samples. These samples were
also used to establish the plasma antioxidant capacity and
the plasma ACE activity of the SHR. Subsequently, MDA
and reduced glutathione (GSH) concentrations were also
measured in liver samples.
At the end of the experimental period, the 24-week-old
rats were killed by decapitation, and the same tests
and procedures recorded for the killed 20-week-old rats
were applied to these animals as well.
The experiments were designed and performed in
accordance with the European and Spanish legislation
on care and use of experimental animals (2010/63/UE;
Real Decreto 53/2013) and were approved by the Ethics
Committee at the Universidad Complutense de Madrid.
Blood pressure measurements
The systolic blood pressure (SBP) was measured weekly
in the SHR by the tail cuff method with some modifica-
tion as described in Miguel et al. (16), during all the
experimental period. Before the measurements, the rats
were kept at 388C for 1015 min to make the pulsation of
the tail artery detectable. Arterial blood pressure mea-
surements were performed at the same time of the day
(between 9 a.m. and 1 p.m.) in order to avoid the
influence of the circadian cycle, and the values of SBP
were obtained by estimating the average reading of five
measurements.
Plasma and liver samples
The blood samples were collected in tubes containing
lithium heparin as anticoagulant and centrifuged at
3,500g for 20 min to obtain the plasma. A piece of liver
tissue was homogenized at 48C in a potter with phos-
phate-buffered saline (PBS) (0.01 M PBS, 0.15 M NaCl,
pH 7.4). The homogenates of liver were centrifuged at
5,000g for 15 min at 48C, and the supernatant was
recovered. Plasma samples and supernatants of liver
samples were stored at 808C until the analysis. Protein
content in the liver samples was determined by the
spectrophotometric technique (DC protein assay, Biorad,
Michigan, USA). We used bovine serum albumin as
standard (Sigma-Aldrich, Milwaukee, WI, USA).
Determination of glucose, total cholesterol, and
triglycerides
Glucose, total cholesterol, and the triglyceride levels in
the plasma of the animals were determined using colori-
metric assays from Spinreact (Girona, Spain), according
to the manufacturer instructions. The plasma values were
expressed as mg/dL.
Determination of plasma antioxidant capacity
The antioxidant capacity of the plasma samples was deter-
mined using the oxygen radical absorbance capacity-
fluorescein (ORAC) assay, previously described by Manso
et al. (17). The final assay mixture (200 ml) contained 20 ml
of the plasma samples or 20 ml of Trolox (Sigma-Aldrich, St.
Louis, MO, USA) [6-hydroxy-2,5,7,8-tetramethylchroman-
2-carboxylic acid] at different concentrations (18 mM) as
Table 1. Composition of total, soluble and insoluble, fiber; total
polyphenols, procianidine; and antioxidant capacity of soluble
cocoa fiber product
Total dietary fiber (g/mg product) 46.50
Soluble fiber 42.80
Insoluble fiber 3.70
Total polyphenols (g/mg product) 2.24
Total procianidine 0.032
ORAC Total (mmol TE/g) 569
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standard. Samples and standards were dissolved in
75 mM PBS (pH 7.4). Disodium fluorescein (70 nM)
(Sigma-Aldirch Log, Schnelldorf, Germany) as oxidizable
substrate was prepared using the same buffer and stored
in dark conditions at 48C for a maximum of 4 weeks,
and 2,2?-azobis (2-methylpropionamidine) (AAPH)
(12 mM) (Sigma-Aldrich, Milwaukee, WI, USA) was used
as oxygen radical generator. The AAPH solution was
prepared using 75 mM PBS (pH 7.4) just before the
analysis. For the blank, the plasma was substituted by
20 ml of PBS. A Polarstar Galaxy plate reader (BMG
Labtechnologies GmbH, Offenburg, Germany) with a
485-P excitation and a 520-P emission filter was used. The
fluorescent plate reader was controlled by the Fluostar
Galaxy software version (4.11-0). Black 96-well micro-
plates (96F untreated microwell, NuncTM, Denmark)
were used. Fluorescence measurement was carried out at
378C and was recorded every minute for 40 min. All
reaction mixtures were prepared in duplicate, and at least
three independent runs were performed for each sample.
ORAC values were calculated and expressed as mmol
Trolox/ml plasma.
Determination of malondialdehyde
Plasma and liver MDA values were measured by a
thiobarbituric acid (TBA) assay, previously described by
Rodrı´guez-Martı´nez and Ruiz-Torres (18) and modified
by Quin˜ones et al. (19). Plasma and hepatic tissue
samples were incubated with NaOH for 30 min, and the
samples were then mixed with 20% trichloroacetic acid in
0.6 M HCl (1:1, v/v). The tubes were kept on ice for
20 min to precipitate components and to avoid possible
interferences. The samples were centrifuged at 1,500g
for 15 min before adding TBA (120 mM in Tris 260 mM,
pH 7) to the supernatant in a proportion of 1:5 (v/v);
then, the mixture was boiled at 978C for 30 min. Spectro-
photometric measurements at 535 nm were made at 208C.
The plasma MDA values were expressed as nmol MDA/ml
plasma, and the liver MDA values were expressed as nmol
MDA/mg tissue protein.
Determination of reduced glutathione
The reduced glutathione (GSH) levels in the liver were
determined using the monochlorobimane (mCB) method
described by Kamencic et al. (20). The final assay mixture
(100 ml) contained 90 ml of the liver samples or of reduced
glutathione as standard (Sigma-Aldrich Chemie CMBh,
Germany) in a PBS solution (pH 7.4) at different con-
centrations (0.00110 Mm) and 10 ml of glutathione
S-transfer (1 U/ml) obtained from equine liver and mono-
chlorobimane (1 mM) (Fluka Biochemical, Swaziland).
The samples were then allowed to incubate in dark at
room temperature for 30 min. The GSHmCB adduct
was measured using a Labsystems Fluoroskan II micro-
titer reader with excitation at 380 nm and the emission
was measured at 470 nm. The liver GSH levels were
expressed as mmol GSH/mg tissue protein.
Determination of ACE activity
The ACE activity in the plasma samples was measured
by a fluorimetric method as explained by Miguel et al.
(21).Then, triplicate plasma (3 ml) was incubated for
15 min at 378C with 40 ml of assay buffer containing the
ACE substrate 5 mM Hip-His-Leu (Sigma). The reaction
was stopped by the addition of 190 ml of 0.35 N HCl.
The product generated, His-Leu, was measured fluor-
imetrically following 10 min incubation with 100 ml of 2%
o-phthaldialdehyde in methanol. Fluorescence measure-
ments were carried out at 378C in a Fluostar Optima plate
reader (BMG Labtech, GmbH, Offenburg, Germany)
with 350-nm excitation and 520-nm emission filters. The
fluorescent plate reader was controlled by the Fluostar
Optima software. Black 96-well polystyrene microplates
(Biogen Cientı´fica, Madrid, Spain) were used. A calibra-
tion curve with ACE from rabbit lung (Sigma, St. Louis,
MO) was included in each plate. The ACE activity was
expressed as mU ACE/ml plasma.
Statistical analysis
The results are expressed as mean values9standard error
of the mean (SEM) for a minimum of four rats and were
analyzed by a one- or two-way analysis of variance
(ANOVA) and the differences between the groups were
assessed by the Bonferroni test and Student t test, using
the GraphPad Prism software. We considered as the
treatment period the time elapsed from the 10th until the
20th week of life and we considered the follow-up period
from the 20th to the 24th week of life. Differences
between the means were considered to be significant
when the p values were B0.05.
Results
Arterial blood pressure
The SBP of the different groups of SHR are shown in
Fig. 1. SHR of the negative control group that consumed
tap water experienced a gradual increase in SBP from
the start of the study, when the animals were 10 weeks
old, which reached maximal values at about 1920 weeks
of life. From this age, the SBP of these rats remained
constantly high and presented similar values until the
24th week of life. Hypertension was decreased in the
SHR groups treated with 50 mg/kg/day captopril or with
400 mg/kg/day SCFP. From the 10th to the 20th week of
life (treatment period), the lowest values of SBP were
observed in the rats of the positive control group that
were treated with captopril. The dose of 400 mg/kg/day of
SCFP also decreased hypertension in SHR. This group
showed lower values of SBP than the animals from the
negative control group. However, the animals treated
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with 200 mg/kg/day SCFP 800 mg/kg/day SCFP or
800 mg/kg/day BETA-G did not show any antihyperten-
sive effect, and the values of SBP in these groups were
quite similar to those of the negative control group. The
SHR that had been treated with 400 mg/kg/day SCFP
showed an increase in SBP when they were given, at the
20th week of life, tap water as drinking fluid. Moreover,
these animals achieved SBP values similar to those of the
negative control group during the follow-up period. SBP
also increased in the SHR that had received captopril
when the pharmacological treatment finished, but in this
case the reversion of the antihypertensive effect was less
abrupt than when the treatment with 400 mg/kg/day
SCFP was disrupted (Fig. 1).
Body weight increased progressively in all groups of
rats from the beginning of the study, and throughout the
experimental period, the growth was quite similar in the
SHR treated with SCFP or BETA-G and in the negative
control rats. However, from the 15th weeks of life, the
body weight in the captopril group was slightly lower than
in the remaining groups (data not shown). Food intake
was also very similar in all groups along the experimental
period (data not shown), but some differences could be
observed in the fluid intake, even if it usually varied in all
animals. In this context, we can stand out that the fluid
intake in the SHR treated with 50 mg/kg/day captopril or
800 mg/day BETA-G was higher than that in the other
rats (pB0.05). When these treatments were disrupted, a
reduction in the fluid intake was observed in the rats;
however the animals that had been treated with 800 mg/
day BETA-G maintained a drinking behavior slightly
more pronounced than those of the other groups until the
end of the experimental period (data not shown).
Glycaemia and lipid profile
Plasma glucose was lower in the SHR that had been treated
with 400 mg/kg/day SCFP or 800 mg/kg/day BETA-G
than in the SHR that consumed tap water (negative control
group). The animals treated with the remaining doses
of SCFP also showed a slight decrease in glycaemia
when compared with the negative control group, but no
significant differences were appreciated in these compar-
isons. In addition, plasma glucose in the SHR treated with
50 mg/kg/day captopril was similar to plasma glucose
in the negative control group. After the follow-up period,
the glycaemia differences mentioned above could not be
observed. Nevertheless, plasma glucose significantly in-
creased in the animals that had been treated with 400 mg/
kg/day SCFP when the treatment was disrupted (Fig. 2).
Total plasma cholesterol and plasma triglycerides were
also lower in the SHR that had been treated with 400 mg/
kg/day SCFP or 800 mg/kg/day BETA-G, than in the
group that consumed tap water (negative control group).
No differences were observed in these parameters in the
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Fig. 1. Systolic blood pressure (SBP) of spontaneously hypertensive rats. The animals consumed different fluids from the 10th
week of life until the 20th weeks of life (T treatment period, indicated by a white bar) and received different daily treatments: tap
water (k), 50 mg/kg/day captopril (h), 200 mg/kg/day soluble cocoa fiber product (SCFP) ("), 400 mg/kg/day SCFP (j), 800 mg/
kg/day SCFP ('), and 800 mg/kg/day beta-glucan 0.75 mm (BETA-G) (x). The rats consumed tap water from the 20th week of life
until the 24th week of life (F follow-up period, indicated by a black bar). Data are mean values9SEM for 8 animals in T and for
4 animals in F. p estimated by two-way ANOVA and Bonferroni test (pB0.05). Similar letters represent no statistical differences.
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SHR that had received the remaining treatments and the
rats that were not treated. In accordance with glucose
results, total cholesterol and triglycerides in the plasma
significantly increased in the animals that had been treated
with 400 mg/kg/day SCFP or 800 mg/kg/day BETA-G
when the treatment finished (Figs. 3 and 4).
Redox status
No differences were observed in plasma ORAC values
and in liver reduced glutathione levels in the rats, neither
at the end of the treatment period (20th week of life) nor
at the end of the follow-up period (24th week of life)
(data not shown). However, plasma MDA levels were
lower in the SHR that had been treated with 400 mg/kg/
day SCFP or 800 mg/kg/day SCFP, than in the SHR that
consumed tap water (negative control group). Never-
theless, the plasma MDA levels in the SHR treated with
50 mg/kg/day captopril, 200 mg/kg/day SCFP or 800 mg/
kg/day BETA-G, showed no significant differences
when compared with the negative control group. When
the corresponding treatments were disrupted, the plasma
MDA levels of the groups that had been treated with 400
mg/kg/day SCFP or 800 mg/kg/day SCFP increased, and,
at the 24th week of life, this biomarker was similar in all
the animals (Fig. 5a). Liver MDA levels were somewhat
lower in the SHR treated with 50 mg/kg/day captopril or
400 mg/kg/day SCFP, than in the control SHR, even if
the differences did not attained significant relevance.
When captopril treatment was disrupted, the rats main-
tained decreased levels of liver MDA, but, after the
follow-up period, liver MDA levels increased in the rats
that had been treated with 400 mg/kg/day SCFP. In fact,
at the 24th week of life, this biomarker was similar
in these animals and in the SHR of the control group
(Fig. 5b).
Plasma ACE activity
The ACE activity was significantly higher in the plasma
of the SHR that had been treated with 50 mg/kg/day
captopril than in the control group, but the plasma
activity of this enzyme decreased in the captopril group
when this treatment was disrupted. In fact, the plasma
ACE activity of the rats that had been treated with
captopril was similar to the corresponding values in the
control rats at the end of the follow-up period. A slight,
but not significant, increase of the plasma ACE activity
was also observed in the rats treated with 800 mg/kg/day
SCFP or 800 mg/kg/day BETA-G, and the animals
of these groups showed also a decrease in the plasma
activity of this enzyme when these treatments finished
(data not shown).
Discussion
Fiber components organize functions of the large intestine
and have important physiological effects on glucose, lipid
metabolism, and mineral bioavailability (22). However, as
800 mg/kg CFP [c, f, i, k, l (T); c, g, h (F)] 800 mg/kg BETA-G [d, g, j, k, m (T); d, g, i (F)]
400 mg/kg CFP [e, i, j, (T); b, f, (F)]200 mg/kg CFP [a, e, f, g, h (T); a, f (F)]
Water [a, c, d (T); a, b, c, d, e (F)] 50 mg/kg Captopril [d, h, l, m(T); e, h, i (F)]
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Fig. 2. Histograms of plasma glucose levels (mg/dl) from spontaneously hypertensive rats. The animals consumed different
fluids from the 10th week of life until the 20th weeks of life (T treatment period) and received different daily treatments: tap
water (h), 50 mg/kg/day captopril (j), 200 mg/kg/day soluble cocoa fiber product (SCFP) ( ), 400 mg/kg/day SCFP ( ), 800
mg/kg/day SCFP ( ), and 800 mg/kg/day beta-glucan 0.75 mm (BETA-G) ( ). The rats consumed tap water from the 20th week
of life until the 24th week of life (follow-up periodF). Data are mean values9SEM for 8 animals in T and for 4 animals in F.
p estimated by one-way ANOVA and Bonferroni test between data from different groups, and by student t test on the same
group at the end of T and at the end of F (pB0.05). Similar letters or symbols represent no statistical differences.
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mentioned earlier, the effect of dietary fiber on arterial
blood pressure has not been clearly established. Hyperten-
sion is a chronic pathology that requires chronic treat-
ment, and the long-term administration of functional
products without side effects is an attractive possibility for
the patients with this pathology. In this context, we have
studied the long-term effect of the SCFP in SHR.
The development of hypertension in SHR is very similar
to that in humans (23) and, nowadays, these animals
are considered the best experimental model to evaluate
antihypertensive functional food ingredients (24). There
is an initial period in the life of the SHR in which arterial
blood pressure clearly increases (23, 25). Nevertheless,
from the 10th week of life, the SHR show more stable
values of this variable. The present study was carried out
with 10- to 24-week-old SHR. Along this period, we could
observe that captopril, and also SCFP, clearly decreased
SBP in these animals. As expected, the drug was more
effective in reducing arterial blood pressure than the fiber
product, but it is important to notice that captopril is an
antihypertensive agent with recognized clinical efficacy.
Moreover, our research group characterized the dose of
captopril in this study (50 mg/kg/day) as a high dose that
causes the maximum effect when it was short term
administered to the SHR (data not shown). In addition,
we want to highlight that the decrease in SBP caused by
400 mg/kg/day SCFP was consistent throughout the
treatment period. In contrast, the decrease in SBP could
not be observed in the rats treated with BETA-G.
As Table 1 shows, the SCFP contains polyphenols
and we believe that these compounds could be the agents
responsible for the antihypertensive effect of this fiber
product. It should be noted that the increase in the dose
of SCFP was not always accompanied with an increased
antihypertensive effect in the SHR. In particular, the
highest dose of SCFP (800 mg/kg/day) caused minimal
effect in these animals than the 400 mg/kg/day dose.
This paradox of a no dose-dependent antihypertensive
effect had been observed earlier by our research group
with different polyphenols and polyphenol-rich products,
which we have evaluated also in SHR (26, 27). Polyphe-
nolic compounds act as natural antioxidants and have
interesting benefits to health, but high doses of polyphe-
nols might not always be needed to manifest beneficial
biological activities (28). In addition, several studies show
controversial results of exogenous antioxidants, debating
the type, dosage, and matrix of these compounds that
determine the balance between beneficial and deleterious
effects (29), and it is known that polyphenols can even act
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Fig. 3. Histograms of plasma total cholesterol levels (mg/dl) from spontaneously hypertensive rats. The animals consumed
different fluids from the 10th week of life until the 20th weeks of life (T treatment period) and received different daily
treatments: tap water (h), 50 mg/kg/day captopril (j), 200 mg/kg/day soluble cocoa fiber product (SCFP) ( ), 400 mg/kg/day
SCFP ( ), 800 mg/kg/day SCFP ( ), and 800 mg/kg/day beta-glucan 0.75 mm (BETA-G) ( ). The rats consumed tap water
from the 20th week of life until the 24th week of life (Ffollow-up period). Data are mean values9SEM for 8 animals in T and for
4 animals in F. p estimated by one-way ANOVA and Bonferroni test between data from different groups, and by student
t test on the same group at the end of T and at the end of F (pB0.05). Similar letters or symbols represent no statistical differences.
Sandra Ferna´ndez-Vallinas et al.
6
(page number not for citation purpose)
Citation: Food & Nutrition Research 2016, 60: 29418 - http://dx.doi.org/10.3402/fnr.v60.29418
as pro-oxidants under certain conditions, such as high
doses or the presence of metal ions (29, 30).
We should discard in any case that other possible
compounds of SCFP that differ from polyphenols could
be implicated in the antihypertensive effect of this fiber
product. It is known that cocoa products are also rich in
minerals, such as magnesium, potassium, and calcium,
which have antihypertensive properties (10, 11, 31), but
the SCFP did not contain significant quantities of these
minerals. SCFP contains theobromine, and theobromine
relaxes arterial tissue, but we could also discard this
xanthine as the main responsible agent for the antihyper-
tensive effect of SCFP. As we hare mentioned, the effect
of SCFP is not dose-dependent but the arterial effects
of theobromine are dose-dependent (32). Likewise, it
has been reported that theobromine form cocoa does
not affect blood pressure in healthy and hypertension
type I subjects (33).
When captopril and SCFP treatments were disrupted,
arterial blood pressure rose gradually in the rats. This
confirms the antihypertensive properties of these treat-
ments. In fact, at the end of the follow-up period, the SBP
values were similar in all groups of the SHR. Having in
mind the marked effect of captopril, it was not surprising
to observe that the reversion of the antihypertensive effect
was slower in the group that had received this drug than in
the group that had been treated with the SCFP.
The SHR treated with captopril gained weight at a
lower rate than did other animals, and these findings
agree with previous studies showing that blockade of
ACE system slows body weight gain in this rat strain (34).
We have observed that food intake was similar in all
animal groups. Nevertheless, liquid intake increased mar-
kedly in the rats that had ingested the captopril solution.
This is not surprising because it has been demonstrated
that ACE inhibitors induce thirst and increase water intake
and urine output in rats (35). The animals treated with the
highest dose of fiber (800 mg/kg/day CFP or 800 mg/kg/
day BETA-G) also drank more than the other animal
groups. These data could be related with the water
requirements of fiber to form gels.
According to the European Food Safety Agency, beta-
glucan from any cereal maintains lower cholesterol
levels and decreases plasma glucose levels (36). For these
reasons, we have used BETA-G as a standard fiber to
study these healthy effects. We demonstrated that BETA-G
and SCFP reduced glycaemia in the treated SHR with
20 weeks of life. In addition, we showed that both products
reduced plasma cholesterol and triglyceride levels in these
animals. Researchers have demonstrated that dietary fiber
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has beneficial effects on hyperglycaemia and the lipid
profile (3739), but the fiber product that we have studied
could be, in particular, useful in the subjects in which these
metabolic complications were associated with elevated
arterial blood pressure.
It is well known that antioxidant therapy has positive
results on hypertensive patients (10, 40). Therefore, in
this study, we evaluated the plasma antioxidant capacity
of the rats after the different treatments. We have also
analyzed MDA in the plasma and the liver of the rats
because this metabolite is a biomarker that enabled us to
estimate lipid peroxidation. In addition, GSH, an im-
portant antioxidant tripeptide that prevents damage
caused by free radicals and peroxides, was also measured
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in the rats. The most effective antihypertensive dose of
SCFP (400 mg/kg/day) significantly decreased plasma
and liver MDA values. As in the case of arterial blood
pressure, MDA also returned to basal values when this
treatment finished. Therefore, the SCFP could attenuate
plasma-transported lipids and their peroxidation, im-
proving therefore the cardiovascular conditions. Our
research group demonstrated that the short-term admin-
istration of SCFP decreases both arterial blood pressure
and the ORAC values of the SHR (unpublished data).
Nevertheless, we did not obtain significant results in the
ORAC and GSH determinations of our rats perhaps
because the prolonged period of treatment sets up pro-
oxidant compensatory mechanisms.
ACE is critical for blood pressure control, and specific
inhibitors of this enzyme are used as antihypertensive drugs.
Polyphenols can inhibit this enzyme invitro (41, 42). To better
elucidate the antihypertensive mechanism of the SCFP, we
have also verified the plasma ACE activity in all rat groups.
The plasma ACE activity was significantly higher in the 50
mg/kg/day captopril treated animals than in the remaining
SHR. It is important to highlight that long-term adminis-
tration of ACE inhibitors causes an increase in plasma ACE
(4345) and also that the ACE activity in the vascular tissue
of SHR increases in particular during the long-term treat-
ment with inhibitors of this enzyme (46). A slight, but not
significant, increase of the plasma ACE activity was also
observed in the rats treated with the highest dose of SCFP,
but more studies are needed to clarify if SCFP polyphenols
may act by inhibiting ACE.
In conclusion, long-term intake of SCFP improves
SBP, glycaemia, and lipid profile in SHR. The SCFP also
decrease lipid peroxidation in these animals. All these effects
could indirectly promote a decrease in arterial blood pressure,
but we should not forget that this fiber product contains
polyphenols, and that these agents have demonstrated
antioxidant properties and antihypertensive effect. Therefore,
fiber products could benefit hypertension and related meta-
bolic diseases, and the SCFP could in particular benefit this
pathology. This study supports polyphenols are that respon-
sible, at least in part, for the SCFP antihypertensive effect,
and suggest, after appropriate clinical trials, to consider
this product as a possible functional food ingredient for
hypertensive patients.
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